Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded MGA’s Alex Brill submitted a letter in response to a request for information from the Federal Trade Commission. The FTC was looking for information regarding the business practices of pharmacy benefit...
MGA Analysis of Potential Savings from Complex Generics Cited in Multiple Publications This week, three publications in the healthcare policy and regulatory affairs industries referenced MGA’s recent report on the potential savings from accelerating US approval...
New MGA Report on the Potential Savings from Accelerating US Approval of Complex Generics Matrix Global Advisors (MGA) today released a new report, “Potential Savings from Accelerating US Approval of Complex Generics,” by MGA founder and CEO Alex Brill....
Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually Scott Wooldridge | BenefitsPro “The report, from Matrix Global Advisors and the Coalition for Affordable Prescription Drugs (CAPD), looked at five prescription drugs:...
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says Maia Anderson | Becker’s Hospital Review “An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S....
